Octreotide therapy for control of acute gastrointestinal bleeding in children

Y. Eroglu, K. M. Emerick, P. F. Whitingon, Estella M Alonso*

*Corresponding author for this work

Research output: Contribution to journalReview article

54 Citations (Scopus)

Abstract

Objectives: To evaluate the outcomes of octreotide use in children with gastrointestinal bleeding with or without portal hypertension. Methods: The medical charts of children who received continuous octreotide infusion for the indication of gastrointestinal bleeding from January 1995 to December 2000 were retrospectively reviewed. Results: Twenty-one children with portal hypertension received octreotide infusions (1-2 μg/kg/h) during 35 gastrointestinal bleeding episodes. The duration of infusion ranged from 19 hours to 7 days. Bleeding ceased in 71% of children. Post-treatment rebleeding occurred in 52%, and the mortality was 19%. Response to octreotide, rebleeding, and mortality did not differ significantly between patients with or without intrinsic liver disease. Twelve children with gastrointestinal bleeding unrelated to portal hypertension received octreotide during 14 episodes. The duration of octreotide ranged from 3 hours to 36 days. Fifty percent of children had resolution of bleeding during the infusion. Post-treatment rebleeding occurred in 29%, and the mortality was 50%. No major adverse events were observed in either group. Conclusions: A high rate of bleeding control was achieved with octreotide during acute gastrointestinal bleeding in children with portal hypertension. However, controlled studies are needed for more definitive description of its clinical effects. The role of octreotide is less clear in gastrointestinal bleeding unrelated to portal hypertension.

Original languageEnglish (US)
Pages (from-to)41-47
Number of pages7
JournalJournal of Pediatric Gastroenterology and Nutrition
Volume38
Issue number1
DOIs
StatePublished - Jan 1 2004

Fingerprint

Octreotide
Hemorrhage
Portal Hypertension
Therapeutics
Mortality
Liver Diseases

Keywords

  • Gastrointestinal bleeding
  • Octreotide
  • Portal hypertension

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Gastroenterology

Cite this

@article{274d9237b06046c6843f4c26891e6b81,
title = "Octreotide therapy for control of acute gastrointestinal bleeding in children",
abstract = "Objectives: To evaluate the outcomes of octreotide use in children with gastrointestinal bleeding with or without portal hypertension. Methods: The medical charts of children who received continuous octreotide infusion for the indication of gastrointestinal bleeding from January 1995 to December 2000 were retrospectively reviewed. Results: Twenty-one children with portal hypertension received octreotide infusions (1-2 μg/kg/h) during 35 gastrointestinal bleeding episodes. The duration of infusion ranged from 19 hours to 7 days. Bleeding ceased in 71{\%} of children. Post-treatment rebleeding occurred in 52{\%}, and the mortality was 19{\%}. Response to octreotide, rebleeding, and mortality did not differ significantly between patients with or without intrinsic liver disease. Twelve children with gastrointestinal bleeding unrelated to portal hypertension received octreotide during 14 episodes. The duration of octreotide ranged from 3 hours to 36 days. Fifty percent of children had resolution of bleeding during the infusion. Post-treatment rebleeding occurred in 29{\%}, and the mortality was 50{\%}. No major adverse events were observed in either group. Conclusions: A high rate of bleeding control was achieved with octreotide during acute gastrointestinal bleeding in children with portal hypertension. However, controlled studies are needed for more definitive description of its clinical effects. The role of octreotide is less clear in gastrointestinal bleeding unrelated to portal hypertension.",
keywords = "Gastrointestinal bleeding, Octreotide, Portal hypertension",
author = "Y. Eroglu and Emerick, {K. M.} and Whitingon, {P. F.} and Alonso, {Estella M}",
year = "2004",
month = "1",
day = "1",
doi = "10.1097/00005176-200401000-00011",
language = "English (US)",
volume = "38",
pages = "41--47",
journal = "Journal of Pediatric Gastroenterology and Nutrition",
issn = "0277-2116",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

Octreotide therapy for control of acute gastrointestinal bleeding in children. / Eroglu, Y.; Emerick, K. M.; Whitingon, P. F.; Alonso, Estella M.

In: Journal of Pediatric Gastroenterology and Nutrition, Vol. 38, No. 1, 01.01.2004, p. 41-47.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Octreotide therapy for control of acute gastrointestinal bleeding in children

AU - Eroglu, Y.

AU - Emerick, K. M.

AU - Whitingon, P. F.

AU - Alonso, Estella M

PY - 2004/1/1

Y1 - 2004/1/1

N2 - Objectives: To evaluate the outcomes of octreotide use in children with gastrointestinal bleeding with or without portal hypertension. Methods: The medical charts of children who received continuous octreotide infusion for the indication of gastrointestinal bleeding from January 1995 to December 2000 were retrospectively reviewed. Results: Twenty-one children with portal hypertension received octreotide infusions (1-2 μg/kg/h) during 35 gastrointestinal bleeding episodes. The duration of infusion ranged from 19 hours to 7 days. Bleeding ceased in 71% of children. Post-treatment rebleeding occurred in 52%, and the mortality was 19%. Response to octreotide, rebleeding, and mortality did not differ significantly between patients with or without intrinsic liver disease. Twelve children with gastrointestinal bleeding unrelated to portal hypertension received octreotide during 14 episodes. The duration of octreotide ranged from 3 hours to 36 days. Fifty percent of children had resolution of bleeding during the infusion. Post-treatment rebleeding occurred in 29%, and the mortality was 50%. No major adverse events were observed in either group. Conclusions: A high rate of bleeding control was achieved with octreotide during acute gastrointestinal bleeding in children with portal hypertension. However, controlled studies are needed for more definitive description of its clinical effects. The role of octreotide is less clear in gastrointestinal bleeding unrelated to portal hypertension.

AB - Objectives: To evaluate the outcomes of octreotide use in children with gastrointestinal bleeding with or without portal hypertension. Methods: The medical charts of children who received continuous octreotide infusion for the indication of gastrointestinal bleeding from January 1995 to December 2000 were retrospectively reviewed. Results: Twenty-one children with portal hypertension received octreotide infusions (1-2 μg/kg/h) during 35 gastrointestinal bleeding episodes. The duration of infusion ranged from 19 hours to 7 days. Bleeding ceased in 71% of children. Post-treatment rebleeding occurred in 52%, and the mortality was 19%. Response to octreotide, rebleeding, and mortality did not differ significantly between patients with or without intrinsic liver disease. Twelve children with gastrointestinal bleeding unrelated to portal hypertension received octreotide during 14 episodes. The duration of octreotide ranged from 3 hours to 36 days. Fifty percent of children had resolution of bleeding during the infusion. Post-treatment rebleeding occurred in 29%, and the mortality was 50%. No major adverse events were observed in either group. Conclusions: A high rate of bleeding control was achieved with octreotide during acute gastrointestinal bleeding in children with portal hypertension. However, controlled studies are needed for more definitive description of its clinical effects. The role of octreotide is less clear in gastrointestinal bleeding unrelated to portal hypertension.

KW - Gastrointestinal bleeding

KW - Octreotide

KW - Portal hypertension

UR - http://www.scopus.com/inward/record.url?scp=3142642632&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3142642632&partnerID=8YFLogxK

U2 - 10.1097/00005176-200401000-00011

DO - 10.1097/00005176-200401000-00011

M3 - Review article

C2 - 14676593

AN - SCOPUS:3142642632

VL - 38

SP - 41

EP - 47

JO - Journal of Pediatric Gastroenterology and Nutrition

JF - Journal of Pediatric Gastroenterology and Nutrition

SN - 0277-2116

IS - 1

ER -